Introduction

Pulmonary hypertension (PH) is a progressive disorder defined by mean pulmonary artery pressure exceeding 20 mmHg at rest. If left unmanaged, the sustained pressure overload leads to right ventricular hypertrophy, failure, and premature death. Because early symptoms—exertional dyspnea, fatigue, syncope—are nonspecific, diagnosis is often delayed until advanced disease has developed. Over the past two decades, noninvasive imaging has emerged as a cornerstone for both detecting PH and longitudinally tracking its course. This article examines how advanced imaging modalities complement clinical assessment, hemodynamic measurements, and biomarker testing to improve patient outcomes.

Understanding Pulmonary Hypertension: Pathophysiology and Clinical Need

Pulmonary hypertension encompasses a spectrum of disorders, classified into five groups by the World Health Organization (WHO). Group 1 includes pulmonary arterial hypertension (PAH), often idiopathic or associated with connective tissue diseases. Group 2 stems from left heart disease, Group 3 from lung diseases or hypoxia, Group 4 from chronic thromboembolic disease, and Group 5 from multifactorial mechanisms. Regardless of etiology, the final common pathway involves remodeling of the pulmonary arterioles—intimal proliferation, medial hypertrophy, and fibrosis—that increases resistance to blood flow.

The right ventricle (RV) is poorly adapted to afterload. As pulmonary vascular resistance rises, the RV dilates and hypertrophies, eventually leading to reduced cardiac output. Detecting these changes early is critical because treatment can reverse or slow remodeling in some groups, particularly PAH. Imaging provides direct visualization of the pulmonary vasculature and RV structure and function, enabling clinicians to confirm the diagnosis, assess severity, monitor treatment response, and predict prognosis.

Role of Advanced Imaging Techniques

While right heart catheterization remains the gold standard for measuring pulmonary artery pressure and calculating pulmonary vascular resistance, imaging plays an irreplaceable adjunctive role. It can identify underlying causes (e.g., left heart disease, lung parenchymal abnormalities, thromboembolic burden), evaluate RV function noninvasively, and provide serial measurements without repeated catheterizations. The primary modalities include echocardiography, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine techniques.

Echocardiography: First-Line Screening and Surveillance

Transthoracic echocardiography is the most widely used screening test for PH. It estimates systolic pulmonary artery pressure from the tricuspid regurgitation jet velocity using the Bernoulli equation. Additionally, it provides qualitative and quantitative assessment of RV size, wall thickness, and systolic function (e.g., tricuspid annular plane systolic excursion, fractional area change). Echocardiographic signs of RV pressure overload—such as interventricular septal flattening, right atrial enlargement, and reduced RV longitudinal strain—can suggest PH even when tricuspid regurgitation is absent.

Recent advances, including three-dimensional echocardiography and speckle-tracking strain imaging, have improved the accuracy of RV volume and function measurements. These techniques allow earlier detection of subclinical RV dysfunction and better discrimination between adaptive and maladaptive remodeling. However, echocardiography is operator-dependent and may underestimate or overestimate pressures, particularly in patients with poor acoustic windows. Therefore, it is best used as a screening tool, with abnormal findings prompting further imaging and catheterization.

Computed Tomography Angiography (CTA): Characterizing Vascular Anatomy

CT pulmonary angiography provides high-resolution, isotropic images of the pulmonary arteries down to the segmental level. It is essential for detecting chronic thromboembolic disease (WHO Group 4), where organized clot partially recanalizes and causes increasing resistance. CTA can also identify features suggestive of PAH, such as a main pulmonary artery diameter ≥ 29 mm, which strongly correlates with elevated pressures. Additional findings include enlarged right atrium, pericardial effusion, and mosaic attenuation patterns on inspiratory images—indicators of heterogeneous perfusion.

Newer CT techniques, such as dual-energy CT and CT perfusion, yield functional information about regional lung perfusion and iodine distribution, potentially differentiating thromboembolic from nonthromboembolic PH. Electrocardiographic gating can reduce motion artifacts and allow simultaneous assessment of coronary arteries. The main limitations are radiation exposure, need for iodinated contrast, and limited ability to quantify RV function compared to MRI.

Cardiac Magnetic Resonance Imaging (CMR): Gold Standard for Right Ventricular Assessment

Cardiac MRI is considered the reference standard for RV volumes, mass, and ejection fraction. Unlike echocardiography, CMR does not rely on geometric assumptions and provides highly reproducible measurements. Cine gradient-echo sequences allow assessment of wall motion and septal dynamics; late gadolinium enhancement at the RV insertion points is a marker of fibrosis and poor prognosis in PAH. Phase-contrast flow imaging quantifies pulmonary artery blood flow, including forward and backward flow volumes, which reflect pulmonary vascular resistance.

4D flow MRI is an emerging technique that measures time-resolved three-dimensional blood flow velocity. It can visualize vortices, helical flow, and abnormal flow patterns in the main pulmonary artery that correlate with disease severity. Feature-tracking analysis of cine images provides RV strain, an early marker of dysfunction that precedes changes in ejection fraction. The absence of ionizing radiation makes CMR ideal for serial monitoring, though availability, longer scanning times, and contraindications in patients with implanted devices (non-MRI-conditional) constrain its widespread use.

Ventilation/Perfusion (V/Q) Scintigraphy: Detecting Chronic Thromboembolic Disease

V/Q scanning remains the recommended initial test for suspected chronic thromboembolic pulmonary hypertension (CTEPH) because of its high sensitivity for detecting unmatched perfusion defects. Planar imaging or single-photon emission computed tomography (SPECT) is used. SPECT V/Q allows three-dimensional reconstruction and improves detection of subsegmental defects compared with planar imaging. The main advantage over CT is the absence of contrast nephropathy risk and lower radiation exposure. False positives may occur in patients with lung parenchymal disease, and the scan cannot provide hemodynamic data.

Advantages of Advanced Imaging in PH Management

Integrating advanced imaging into clinical practice offers multiple benefits. First, it enables earlier diagnosis by detecting structural and functional changes in the RV and pulmonary arteries before overt clinical deterioration. Second, it helps differentiate PH subtypes, guiding appropriate therapy—for example, identifying CTEPH that may be curable with pulmonary endarterectomy or balloon angioplasty. Third, serial imaging tracks disease progression or regression, allowing clinicians to adjust treatment intensity. Fourth, imaging is indispensable for risk stratification: RV size, function, and pattern of remodeling predict long-term survival. Finally, noninvasive imaging reduces reliance on repeated catheterizations, lowering patient risk and health care costs.

Limitations and Challenges

No single imaging technique is perfect. Echocardiography is limited by acoustic windows and operator variability. CT involves ionizing radiation and contrast‑related risks. CMR is time‑consuming and contraindicated in certain patients. V/Q scans may be less specific in the presence of lung disease. Moreover, anatomic findings do not always correlate perfectly with hemodynamics, so imaging cannot replace catheterization for definitive diagnosis. Inter modality variability and lack of standardized protocols across institutions further complicate longitudinal comparisons.

Another challenge is the need for expertise in interpreting advanced imaging data. For example, recognizing early RV fibrosis on CMR or subtle perfusion abnormalities on dual‑energy CT requires subspecialty training. As the population with PH grows, training more radiologists and cardiologists in these techniques will be essential. Additionally, cost and accessibility remain barriers, especially in resource‑limited settings.

Future Directions in Pulmonary Hypertension Imaging

Ongoing research aims to overcome current limitations and improve diagnostic precision. Hyperspectral computed tomography and photon‑counting CT are being studied to reduce radiation dose while maintaining high spatial resolution. In MRI, the development of faster acquisition protocols (compressed sensing, deep‑learning reconstruction) may shorten scan times and improve patient tolerability. Artificial intelligence algorithms are being trained to automate segmentation of RV volumes, detect early signs of PH on routine chest CT, and predict treatment response from imaging data.

Molecular imaging using targeted tracers (e.g., fibroblast activation protein inhibitors for PET) could visualize active vascular remodeling at a cellular level. Such probes may enable detection of inflammatory or fibrotic activity before irreversible structural changes occur. Similarly, hyperpolarized 129‑Xe MRI can assess gas exchange and pulmonary micro‑structure, potentially identifying early lung changes in Group 3 PH. The integration of imaging data with genomics, proteomics, and wearable sensors will likely drive a shift toward precision medicine in PH, where therapeutic decisions are individualized based on a patient’s unique disease signature.

Practical Considerations for Clinicians

When ordering advanced imaging for a patient with suspected or known PH, clinicians should consider the clinical question. For screening, echocardiography is appropriate. If the echocardiogram suggests PH and the patient is a candidate for treatment, proceed with right heart catheterization. For subtype classification, especially if CTEPH is possible, V/Q SPECT or CTA is recommended. For baseline and serial RV assessment, CMR is preferred when feasible. In patients who cannot undergo MRI, gated CT or echocardiography with strain imaging are alternative options.

Communication between referring clinicians and radiologists is vital. The imaging report should include not only descriptive findings but also quantitative measurements (e.g., RV ejection fraction, pulmonary artery diameter, pericardial effusion presence) and a summary of how these relate to the patient’s PH probability. Standardized reporting templates, such as those from the Radiological Society of North America, can facilitate consistency and aid clinical decision‑making.

Conclusion

Advanced imaging has transformed the landscape of pulmonary hypertension management. From early detection with echocardiography through detailed anatomical characterization by CT and precise functional quantification by CMR, the armamentarium available to clinicians is powerful and expanding. While each modality has strengths and weaknesses, their combination offers a comprehensive view of the pulmonary circulation and its effect on the right heart. As technological innovations continue—driven by artificial intelligence, molecular probes, and faster acquisition sequences—imaging will only become more integral to diagnosing, monitoring, and ultimately improving outcomes for patients with pulmonary hypertension. Clinicians and radiologists must work collaboratively to harness these tools effectively, ensuring that every patient receives timely, accurate assessment and tailored therapy.

External Resources